anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hematopoietic cell transplantation (HCT) uses cytotoxic chemotherapy and/or radiation followed by intravenous infusion of stem cells to cure malignancies, bone marrow failure and inborn errors of immunity, hemoglobin and metabolism. Lung injury is a known complication of the process, due in part to disruption in the pulmonary microenvironment by insults such as infection, alloreactive inflammation and cellular toxicity. How microorganisms, immunity and the respiratory epithelium interact to contribute to lung injury is uncertain, limiting the development of prevention and treatment strategies. Here we used 278 bronchoalveolar lavage (BAL) fluid samples to study the lung microenvironment in 229 pediatric patients who have undergone HCT treated at 32 children's hospitals between 2014 and 2022. By leveraging paired microbiome and human gene expression data, we identified high-risk BAL compositions associated with in-hospital mortality (P = 0.007). Disadvantageous profiles included bacterial overgrowth with neutrophilic inflammation, microbiome contraction with epithelial fibroproliferation and profound commensal depletion with viral and staphylococcal enrichment, lymphocytic activation and cellular injury, and were replicated in an independent cohort from the Netherlands (P = 0.022). In addition, a broad array of previously occult pathogens was identified, as well as a strong link between antibiotic exposure, commensal bacterial depletion and enrichment of viruses and fungi. Together these lung-immune system-microorganism interactions clarify the important drivers of fatal lung injury in pediatric patients who have undergone HCT. Further investigation is needed to determine how personalized interpretation of heterogeneous pulmonary microenvironments may be used to improve pediatric HCT outcomes.
The invention discloses a medicament for treating hyperosteogeny. 21 grams of each of dry stems, leaves or roots of 24 medicinal materials of wild eucommia ulmoides vines, lygodium japonicum, schefflera arboricola vines, schefflera arboricola trees, paliurus hemsleyanus, caesalpinia cucullata, asiatic toddalia roots, ilexmacrocarpa oliv, wilson passionflower herbs, longtube groundIvy herbs, hypoglaucum schizophragma, laciniate blumea herbs, laciniate blumea stems, carex brownii tucker, passiflora henryi hemsl, champion bauhinia stems, smoothfruit ventilago roots and stems, rhizoma smilacis glabrae, moghania philippinensis, tylophora floribunda miq., cyrtomium fortune, blackberry lily, radix et caulis ventilaginis leiocarpae, fuchsia magellanica and the like are added with 2000 ml of local specially-prepared rice wine (with an alcoholic strength of about 30 degrees) and soaked for 96 hours to obtain the liquid which is the medicament. When in use, the prepared medicinal liquid can be orally taken by patients twice in the morning and in the evening, 21 ml for each time, and the medicinal liquid can be applied to hyperplastic parts of the patients with 12 days as a treatment course. For severe patients, the prepared medicinal liquid can be orally taken by patients for third times in the morning, at noon and in the evening, 21 ml for each time, and the medicinal liquid can be applied to hyperplastic parts of the patients to soften, eliminate, and cure the hyperplastic parts. One treatment course takes 12 days. The medicament of the invention has significant treatment effect after clinical practical application; hyperplastic parts of most patients are softened, eliminated and cured after the medicament is taken for 1-3 treatment courses, and no recurrence occurs.
This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 5 µg. Cohort 1. Two doses (at Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).
PURPOSE:To obtain an emetocathartic composition having enhanced antidiarrhea action, reducing a dose, having a little side effects by blending loperamide hydrochloride with >=a fixed amount of a saccharide. CONSTITUTION:Loperamide hydrochloride is blended with >=3,000 times as much saccharide (e.g. white sugar). The concentration of loperamide hydrochloride in a composition is preferably 0.001-0.02wt%. The blend is properly mixed with a generally usable excipient, lubricant, binder, aroma, coloring agent, pH adjuster to give the objective substance. The objective substance is preferably made into a dosage form such as syrup or dry syrup. By blending loperamide hydrochloride with >=3,000 times as much as the saccharide by weight, anti-diarrhea action is obtained with about 1/3 ordinary dose of loperamide hydrochloride.
The invention discloses a Chinese medicinal composition for treating hyperthyroid heart disease. Hyperthyroid heart disease is induced by sporadic goiter. At the initial stage of hyperthyroid heart disease, a great number of sthenic syndromes, mainly stagnation of liver qi, phlegm congealing, phlegm-blood accumulation and fire due to long-term depression exist. A Chinese medicinal decoction is prepared from Chinese medicinal materials, namely, fiveleaf akebia fruit, largeflower jasmine flower, sword bean, evergreen leaf, sericeous cinquefoil root, Chinese mahonia leaf, plagiopus oederi limpr, tibet milkwort root, five-finger fig root and wild soybean plant which have the effects of soothing the liver, regulating qi, nourishing yin, clearing away heat and invigorating heart and spleen. As proved by clinical test, the total effective rate of the Chinese medicinal composition is up to 97.4 percent, which is remarkably higher than that of a control group. Moreover, the Chinese medicinal composition has the advantages of low treatment cost, simple and convenient method and worthiness of popularization and application.
This study consisted of the Core Study and the Extension Part A and B. The Core Study consisted of 2 phases: Prerandomization and Randomization. The Prerandomization Phase lasted up to 1 week, during which participants were assessed for their eligibility to participate in the study. The Randomization Phase consisted of 3 periods: Titration (6 weeks), Maintenance (13 weeks), and Follow-up (4 weeks; only for those participants not rolling over into the Extension Phase). During the Core Study Titration and Maintenance Periods, participants were randomized into perampanel (2 to 12 mg per day) or placebo treatment groups in a 2:1 ratio within each of the age-matched categories (ie, greater than or equal to 12 to less than 15 and greater than or equal to 15 to less than 18).

The extension phase consisted of part A (Conversion Period - 6 weeks and Maintenance period - 25 weeks) and Part B (Optional Extension Phase -52 weeks). The maximum duration for participation in Part B was 52 weeks.
Pain is the prime symptom of osteoarthritis (OA) that directly affects the quality of life. Protein kinase Cδ (PKCδ/Prkcd) plays a critical role in OA pathogenesis; however, its significance in OA-related pain is not entirely understood. The present study investigated the functional role of PKCδ in OA pain sensation. OA was surgically induced in control (Prkcdfl/fl), global- (Prkcdfl/fl; ROSACreERT2), and sensory neuron-specific conditional knockout (cKO) mice (Prkcdfl/fl; NaV1.8/Scn10aCreERT2) followed by comprehensive analysis of longitudinal behavioral pain, histopathology and immunofluorescence studies. GlobalPrkcd cKO mice prevented cartilage deterioration by inhibiting matrix metalloproteinase-13 (MMP13) in joint tissues but significantly increased OA pain. Sensory neuron-specificdeletion of Prkcd in mice did not protect cartilage from degeneration but worsened OA-associated pain. Exacerbated pain sensitivity observed in global- and sensory neuron-specific cKO of Prkcd was corroborated with markedly increased specific pain mediators in knee synovium and dorsal root ganglia (DRG). These specific pain markers include nerve growth factor (NGF) and vascular endothelial growth factor (VEGF), and their cognate receptors, including tropomyosin receptor kinase A (TrkA) and vascular endothelial growth factor receptor-1 (VEGFR1). The increased levels of NGF/TrkA and VEGF/VEGFR1 were comparable in both global- and sensory neuron-specific cKO groups. These data suggest that the absence of Prkcd gene expression in the sensory neurons is strongly associated with OA hyperalgesia independent of cartilage protection. Thus, inhibition of PKCδ may be beneficial for cartilage homeostasis but could aggravate OA-related pain symptoms.
This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL. Enrollment in the study will sequentially start from the low dose 0.5mL as Group A, then to the mid-dose 1.0mL as Group B and lastly to the high dose of 2.0mL as Group C. Each group will have 16 patients enrolled. The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo (Table 3). As there is no comparable equivalent to YS-HBV-002 available in the market, the placebo of normal saline solution to be injected intramuscularly will serve as the control in this trial. The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo. The vaccination regimen will be 1 IM injection every 3 days in the deltoid muscle, alternately for approximately 6 weeks. A total of 14 injections will be administered to each patient.
The aim of this study is to determine if the offspring of mothers with obesity, present disorders in the expression of genes related to atrophy or protein synthesis in the muscle and if these disorders are modified with the (-)-epicatechin (Epi) treatment. Six male offspring per group were randomly assigned to the control groups [C and offspring of maternal obesity (MO)] or the Epi intervention groups, Epi treatment for 13 weeks (C + Epi long or MO + Epi long), or Epi administration for two weeks (C + Epi short or MO + Epi short). The effect of Epi in the gastrocnemius tissue was evaluated, analyzing mRNA and protein levels of Murf1, MAFbx, Foxo1, NFkB, and p70S6K-alpha. After the analysis by two-way ANOVA, we found an influence of the Epi long treatment over the model, by decreasing the Murf1 gene expression in both groups treated with the flavonoid (C + Epi long and MO + Epi long) (p = 0.036). Besides, Epi long treatment over the NFκB expression, by decreasing the fold increase in both groups treated with the flavonoid (C + Epi long and MO + Epi long) (p = 0.038). We not find any interaction between the variables or changes in the MAFbx, Foxo1 mRNA, neither in the phosphorylated/total protein ratio of NFκB, Foxo1, or p70S6K-alpha. In conclusions, treatment with a long protocol of Epi, reduces the mRNA of the muscle atrophy genes Murf 1 and NFkB, in the gastrocnemius muscle; however, these changes are not maintained at protein level.
The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative disorder, particularly cancer, more particularly metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit EphA2 expression or activity in combination with one or more agents that decrease/inhibit PCDGF or HAAH expression or activity. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2, PCDGF, and/or HAAH agents of the invention that inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. The invention also provides pharmaceutical compositions comprising one or more EphA2 agents of the invention in combination with one or more PCDGF agents of the invention and/or one or more HAAH agents of the invention. In some embodiments, the agents of the invention can be administered with other cancer therapeutic agents that are not EphA2-, PCDGF-, or HAAH-based. Diagnostic methods and methods for screening for therapeutically useful agents of the invention are also provided.
Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
This invention relates to a IFN-beta-cn and its mutant. Different from IFN-beta, The 47th position is methionine instead of leucyl. The difference does not influence its bio-activity. Its mutant has serine on 17th position instead of cysteine. Expression carrier, expression hose, separation, purification and identification are all disclosed. The invention provides good conditions for mass production and clinic application.
FIELD: medicine, immunology. SUBSTANCE: invention provides vaccine compositions of attenuated respiratory-syncytial virus (RSV). Attenuated virus can be a derivative of RSV that was attenuated incompletely by cold passage or by insertions of mutations that make a temperature-sensitive virus (ts) or a phenotype adapted to cold (ca). Invention relates to also a method of stimulation of an immune system of individual for induction of the protection against respiratory-syncytial virus by administration of attenuated RSV. Invention provides also preparing pure cultures of attenuated RSV where this virus is attenuated more completely by the further derivatization (the further derivatives preparing) identified early as incompletely attenuated ts- and cp-mutants. EFFECT: increased levels of the protective immunicity. 29 cl, 17 tbl, 3 ex
The present study explores the modifications of cardiovascular autonomic control (CAC) during wake and sleep time and the systemic inflammatory profile associated with exposure to indoor air pollution (IAP) in a cohort of healthy subjects. Twenty healthy volunteers were enrolled. Indoor levels of fine particulate matter (PM2.5), nitrogen dioxide (NO2) and volatile organic compounds (VOCs) were monitored using a portable detector for 7 days. Together, a 7-day monitoring was performed through a wireless patch that continuously recorded electrocardiogram, respiratory activity and actigraphy. Indexes of CAC during wake and sleep time were derived from the biosignals: heart rate and low-frequency to high-frequency ratio (LF/HF), index of sympathovagal balance with higher values corresponding to a predominance of the sympathetic branch. Cyclic variation of heart rate index (CVHRI events/hour) during sleep, a proxy for the evaluation of sleep apnea, was assessed for each night. After the monitoring, blood samples were collected to assess the inflammatory profile. Regression and correlation analyses were performed. A positive association between VOC exposure and the CVHRI (Δ% = +0.2% for 1 μg/m3 VOCs, p = 0.008) was found. The CVHRI was also positively associated with LF/HF during sleep, thus higher CVHRI values corresponded to a shift of the sympathovagal balance towards a sympathetic predominance (r = 0.52; p = 0.018). NO2 exposure was positively associated with both the pro-inflammatory biomarker TREM-1 and the anti-inflammatory biomarker IL-10 (Δ% = +1.2% and Δ% = +2.4%, for 1 μg/m3 NO2; p = 0.005 and p = 0.022, respectively). The study highlights a possible causal relationship between IAP exposure and higher risk of sleep apnea events, associated with impaired CAC during sleep, and a pro-inflammatory state counterbalanced by an increased anti-inflammatory response in healthy subjects. This process may be disrupted in vulnerable populations, leading to a harmful chronic pro-inflammatory profile. Thus, IAP may emerge as a critical and often neglected risk factor for the public health that can be addressed through targeted preventive interventions.
Fibercolonoscopy, as a terminal examination method for lower digestive tract diseases, often brings different degrees of pain and discomfort, tension and anxiety to patients. Therefore, at present, intravenous anesthesia is often used in clinical practice to reduce discomfort, and intravenous propofol combined with fentanyl is the most widely used in clinical practice. But intravenous general anesthesia can lead to hemodynamic fluctuations and an increase in anesthesiation-related complications such as longer stays in the hospital after surgery. Complications related to sedation and analgesia have attracted increasing attention in recent years. Studies have shown that most of the adverse events in endoscopy are related to the sedation and analgesia drugs used. With the successful application of patient-controlled analgesia (PCA) in the field of postoperative analgesia, this technique has also been used in the sedation and analgesia of gastroenteroscopy in recent years. Propofol has the characteristics of quick action, short time of action and rapid recovery, so it is very suitable for the anesthesia and sedation of painless abortion and painless gastroenteroscopy. Remifentanil, as an opioid μ receptor agonist, is easily hydrolyzed rapidly by non-specific esterases in plasma and tissues due to the ester bond contained in its chemical structure. Therefore, it has unique pharmacokinetic characteristics such as rapid intravenous injection, small volume of distribution, rapid clearance after drug withdrawal, no accumulation, metabolism is not affected by liver and kidney function, and has been widely used in various surgeries in recent years, especially in the anesthesia of short surgeries.
A method processing clinical material for medical research includes receiving samples and accompanying records and providing them with a removable label that is placed over information originally provided on the sample, records or other material. The removable label includes an identifying patient code, but arbitrary to the actual identity of the patient. The patient code is matched with the actual confidential patient information in a generally non-accessible location. The label includes an adhesive whereby the label can be removed without damaging the original information. In this way, the labels can be removed if the materials need to be sent back to the treating physician. Additionally, the use of removable labels enables the individual(s) designated with labeling the material when it comes into the research facility to double check the correctness of the new labeling if necessary. For patient data stored in an electronic or digital format, the researcher can be given an electronic or digital copy of the data labeled with the research patient code identifier but with the confidential patient information obscured electronically. Confidentiality for the researchers can be maintained by having the researches verify, by a written statement or otherwise, that the applied labels have not been removed while the materials were in their possession.
The invention relates to the field of genetic engineering, in particular to a nucleic acid molecule and application thereof as a specific promoter. The present invention provides a nucleic acid molecule having: the nucleotide sequence shown in any of SEQ ID NO. 1-SEQ ID NO. 9. The recombinant promoter obtained through artificial transformation can specifically express exogenous genes in retina structural cells of eyes, reduces expression in non-targeted cells, and can reduce influence on other normal tissues and organs. The length of the recombinant promoter provided by the invention is not more than 500bp, and the recombinant promoter is suitable for the requirement of expressing larger exogenous genes in AAV vectors and has wider application range. The partial promoter provided by the invention has higher expression intensity in PR cells, and is also suitable for certain scenes with higher requirement on the expression quantity of target genes.
The 3-month twelve-session intervention, "Choices", included topics on nutrition, physical activity, and resiliency. Parents, boys and girls met separately. The sessions were developed for delivery by a family physician, two family medicine residents, and a nutritionist, who received training in positive psychology and resilience skills. All children were measured on the same dates, but children were randomly assigned to two cohorts, beginning 6 months apart, to facilitate statistical analysis by having one group experience "normal growth" on study prior to intervention.
Fluctuations in the strength and direction of natural selection through time are a ubiquitous feature of life on Earth. One evolutionary outcome of such fluctuations is adaptive tracking, wherein populations rapidly adapt from standing genetic variation. In certain circumstances, adaptive tracking can lead to the long-term maintenance of functional polymorphism despite allele frequency change due to selection. Although adaptive tracking is likely a common process, we still have a limited understanding of aspects of its genetic architecture and its strength relative to other evolutionary forces such as drift. Drosophila melanogaster living in temperate regions evolve to track seasonal fluctuations and are an excellent system to tackle these gaps in knowledge. By sequencing orchard populations collected across multiple years, we characterized the genomic signal of seasonal demography and identified that the cosmopolitan inversion In(2L)t facilitates seasonal adaptive tracking and shows molecular footprints of selection. A meta-analysis of phenotypic studies shows that seasonal loci within In(2L)t are associated with behavior, life history, physiology, and morphological traits. We identify candidate loci and experimentally link them to phenotype. Our work contributes to our general understanding of fluctuating selection and highlights the evolutionary outcome and dynamics of contemporary selection on inversions.